Many malignant tumors start releasing cancer cells into the circulation long before diagnosis 1 . To create a disseminated population that may eventually progress to overt metastasis, circulating cancer cells must first traverse endothelial capillary walls and then cope with the newly invaded parenchyma. At the distant site, cancer cells have to remain viable as metastasis-initiating entities to eventually grow out as overt metastatic lesions 2 . Specialized microenvironments called metastatic niches are thought to nurse the outgrowth of metastatic nodules from metastasis-initiating cells 3 . The niche components that support these functions remain mostly unknown, but the extracellular matrix may be relevant in this context. The extracellular matrix has a crucial role in developmental patterning, tissue organization and stem cell niches, and its composition is characteristically altered in tumors 4, 5 .
Many malignant tumors start releasing cancer cells into the circulation long before diagnosis 1 . To create a disseminated population that may eventually progress to overt metastasis, circulating cancer cells must first traverse endothelial capillary walls and then cope with the newly invaded parenchyma. At the distant site, cancer cells have to remain viable as metastasis-initiating entities to eventually grow out as overt metastatic lesions 2 . Specialized microenvironments called metastatic niches are thought to nurse the outgrowth of metastatic nodules from metastasis-initiating cells 3 . The niche components that support these functions remain mostly unknown, but the extracellular matrix may be relevant in this context. The extracellular matrix has a crucial role in developmental patterning, tissue organization and stem cell niches, and its composition is characteristically altered in tumors 4, 5 .
With a median survival of <2 years after diagnosis, lung metastasis from breast cancer remains a major clinical challenge 6 . We have identified a set of genes whose expression in breast tumors is associated with lung relapse 7, 8 . Several of these genes encode cytokines and other secreted products that enhance the transendothelial migration of breast cancer cells and their passage from circulation into the lung parenchyma 9, 10 . Another member of this lung metastasis gene set is TNC 7 . We find the possible involvement of TNC in metastasis intriguing, given its properties as an extracellular matrix protein. TNC is a hexameric glycoprotein that binds to fibronectin, periostin 11 , integrin cell adhesion receptors and syndecan membrane proteoglycans 12 . TNC is abundantly expressed in developing bone and cartilage, and in neural crest cells. In adults, TNC is present in stem cell niche regions and at sites of epithelial-mesenchymal interaction. TNC expression is elevated by mechanical stress and inflammation during wound healing and in tumor-associated connective tissue 12, 13 . On the basis of these clues, we wondered whether cancer cells expressing TNC have a selective advantage in the lung microenvironment. Here we provide evidence for such a role, and uncover new links of TNC to the critical stem and progenitor cell pathways NOTCH and WNT 14, 15 , and to the viability of metastatic cancer cells in the lungs.
RESULTS

TNC expression associates with aggressive lung metastasis
TNC is among a set of genes whose mRNA level in breast tumors is associated with relapse in the lungs 7 . To investigate this association, we analyzed TNC by immunostaining in human breast cancer tissue samples. In lung nodules, TNC staining was particularly evident at the invasive front (Fig. 1a) . In lung metastases and in primary tumor samples, a high level of TNC staining was associated with a shorter progression to lung relapse ( Fig. 1b and Supplementary Fig. 1 ). The median time from primary tumor diagnosis to lung metastasis was 24 months in cases with high expression of TNC in metastatic nodules versus 56 months in cases with low TNC (Fig. 1b) . Moreover, high
We report that breast cancer cells that infiltrate the lungs support their own metastasis-initiating ability by expressing tenascin C (TNC). We find that the expression of TNC, an extracellular matrix protein of stem cell niches, is associated with the aggressiveness of pulmonary metastasis. Cancer cell-derived TNC promotes the survival and outgrowth of pulmonary micrometastases. TNC enhances the expression of stem cell signaling components, musashi homolog 1 (MSI1) and leucinerich repeat-containing G protein-coupled receptor 5 (LGR5). MSI1 is a positive regulator of NOTCH signaling, whereas LGR5 is a target gene of the WNT pathway. TNC modulation of stem cell signaling occurs without affecting the expression of transcriptional enforcers of the stem cell phenotype and pluripotency, namely nanog homeobox (NANOG), POU class 5 homeobox 1 (POU5F1), also known as OCT4, and SRY-box 2 (SOX2). TNC protects MSI1-dependent NOTCH signaling from inhibition by signal transducer and activator of transcription 5 (STAT5), and selectively enhances the expression of LGR5 as a WNT target gene. Cancer cell-derived TNC remains essential for metastasis outgrowth until the tumor stroma takes over as a source of TNC. These findings link TNC to pathways that support the fitness of metastasis-initiating breast cancer cells and highlight the relevance of TNC as an extracellular matrix component of the metastatic niche. a r t i c l e s 8 6 8 VOLUME 17 | NUMBER 7 | JULY 2011 nature medicine TNC expression in lung metastatic nodules predicted poor overall survival, as the median time from metastasis diagnosis to death was 7 months in cases with high TNC expression and 34 months for cases with low TNC.
Prompted by these results, we investigated the functional role of TNC in experimental models of breast cancer metastasis to lung. We used two breast cancer cell lines, MDA231-LM2 and CN34-LM1, which have high capacity to colonize the lungs in mice 7, 8 . The corresponding parental cell lines, MDA-MB-231 and CN34, were derived from malignant pleural fluids of patients with advanced metastatic disease. MDA231-LM2 and CN34-LM1 had greater TNC expression than their parental counterparts (Supplementary Fig. 2 ) and readily colonized the lungs when inoculated into the tail vein of immunodeficient mice (Fig. 1c) . The resulting colonies showed a marked pattern of cancer cell-derived (human) TNC deposition, as determined by immunostaining with antibodies to human TNC ( Fig. 1c and Supplementary Fig. 3 ). TNC was uniformly distributed throughout the micrometastases in early stages of lung seeding (Fig. 1c) . As these colonies grew, cancer cell-derived TNC became progressively segregated to the invasive front (Fig. 1c) , similar to its distribution in human metastasis nodules (Fig. 1a) . Another lung metastasis gene product, fascin-1 (refs. 7,10), remained expressed throughout the metastatic nodules (Supplementary Fig. 4a ), indicating that the absence of TNC expression outside the invasive front was not due to a general extinction of metastatic gene expression. The invasive front hosts presumptive cancer stem cells and dynamic interactions with mesenchymal, vascular and inflammatory components of the tumor stroma 16, 17 . Indeed, the TNC-positive areas in macrometastases were infiltrated with myofibroblasts (α-smooth muscle actin-staining cells; Supplementary Fig. 4b ) and macrophages (CD68 + cells; Supplementary Fig. 4c ).
Autocrine TNC initiates micrometastasis outgrowth
When we used shRNAs against TNC, the expression of TNC was reduced by about 90% in MDA231-LM2 and CN34-LM1 cells (Supplementary Fig. 5a ). Control and TNC knockdown cells were injected orthotopically into the mammary fat pad (Fig. 1d) or directly to the lungs through the lateral tail vein (Fig. 1e) . Reduced TNC expression did not diminish the ability of the cancer cells to grow as tumors when 5 × 10 5 cells were implanted in the mammary fat pad of female mice (Fig. 1f) . However, TNC deficiency resulted in 90% inhibition of mammary tumors to metastasize to the lungs (Fig. 1g) . TNC knockdown similarly caused a statistically significant decrease in lung colonization by these cells inoculated via the tail vein, as determined by bioluminescence imaging of a marker luciferase gene, and by H&E staining (Fig. 1h,i and Supplementary Fig. 5b,c) .
TNC influences cell migration in vitro 18 , and its knockdown in the breast cancer cells moderately decreased the cells' ability to migrate through membranes and matrigel ( Supplementary Fig. 6 and ref. 8 ). This decrease was, however, much smaller than the 90% decrease in metastasis observed in vivo. Therefore, we investigated the effect of TNC knockdown on metastatic cell proliferation and survival. At 10 d after cancer cell inoculation into mice, the lung micrometastases showed no statistically significant effect of TNC knockdown on the proliferation marker phosphohistone H3 (Supplementary Fig. 7a,b) . However, the TNC-depleted colonies showed a marked increase in the apoptosis marker, cleaved caspase 3 (Fig. 2a,b) . To temporally map the effect of cancer cell-derived TNC during the course of lung colonization, we generated an MDA231-LM2 line that expresses TNC shRNA under the conditional control of doxycycline ( Supplementary Fig. 8 ). We intravenously inoculated these cells and allowed them to reside in the lungs for different lengths of time before administering doxycycline to suppress TNC expression (Fig. 2c) . A 10 d treatment with doxycycline caused an almost complete clearing of human TNC from established lung nodules (Fig. 2d) . This was accompanied by an increase in apoptosis marker, cleaved caspase 3, at the invasive front (Fig. 2e,f) . The administration of doxycycline starting 2 d or 6 d after cancer cell inoculation inhibited the outgrowth of the incipient micrometastases (Fig. 2g) . When treatment was started later, doxycycline was less effective at curbing metastasis ( Supplementary  Fig. 9a ). Administration of doxycycline at day 21, when the metastatic nodules had already become large, had no effect on further increase of the metastatic load (Fig. 2g) . However, stromal myofibroblasts at the invasive front of large nodules ( Supplementary Fig. 4b ) produce TNC 19 . Indeed, large metastatic nodules stained positive for both cancer cell-derived (human) and stromal (mouse) TNC, whereas the micrometastases expressed only cancer cell-derived TNC (Fig. 2h) . In agreement with this, α-smooth muscle actin, a marker of activated fibroblasts (myofibroblasts) was expressed in late metastatic foci but not in micrometastases (Supplementary Fig. 9b ). Therefore, cancer cells in micrometastases act as their own main source of TNC until the tumor stroma takes over as a source of TNC.
TNC expression and metastasis-initiating characteristics TNC expression has been detected in certain stem cell niches 20, 21 and is abundantly expressed by mammary stem and progenitor cell populations 22 . Pluripotent mammary epithelial cells and metastasisinitiating breast cancer cell populations can grow as floating aggregates, called mammospheres and oncospheres, respectively, when placed on nonadhesive plates in serum-free conditions 22, 23 . We investigated the link between TNC and oncosphere formation in breast cancer cells from malignant pleural effusions obtained from human subjects. Both the recently isolated breast cancer cells and the CN34-LM1 cell line readily formed oncospheres under these culture conditions (Fig. 3a) . Notably, TNC was upregulated in the oncospheres compared to monolayer cultures of the same samples (Fig. 3b) , and was further upregulated after a cycle of oncosphere dissociation and regrowth (Supplementary Fig. 10a ). The pluripotency markers NANOG 24 , OCT4 (refs. 25,26) and SOX2 (ref. 27 ) were upregulated in the oncospheres, and so were the adult stem cell markers MSI1 (also known as Musashi1) 28 and LGR5 (ref. 29 ; Fig. 3c,d) . Moreover, the mammary differentiation marker GATA3 (ref. 30 ) and the TNC-suppressor and metastasis-suppressor microRNA (miRNA) Right, doxycycline induction at day 21, maintained for 2 weeks. Two-tailed Student's t test was used to determine all P values. (h) Immunofluorescence analysis of TNC expression in MDA231-LM2 metastatic foci at different time points during lung colonization. Time points analyzed were days 10 and 36 (D10 and D36, respectively) after intravenous inoculation. Antibodies to stromal derived mouse TNC (mTNC) and tumor cell-derived human TNC (hTNC) were used. DAPI was used for nuclear staining. Scale bar, 20 µm.
miR-335 (ref. 8 ) were expressed at low levels in oncospheres compared to monolayers (Fig. 3e) . Thus, TNC expression was associated with progenitor markers in metastatic breast cancer cell populations.
Regulation of oncosphere growth, MSI1 and
LGR5 by TNC To test the functional implications of this link, we knocked down TNC in CN34-LM1 and in a primary culture of metastatic breast cancer cells from another individual with breast cancer, CN127, and generated oncospheres. TNC depletion (Fig. 4a) did not inhibit the formation of primary oncospheres but severely inhibited the formation of secondary oncospheres under standard culture conditions, and of primary oncospheres under growth factor-deprived conditions ( Fig. 4b  and Supplementary Fig. 10b ). This suggests that TNC is required for the fitness of oncosphere initiating cells, particularly under stress.
Breast cancer cell populations with a CD44 + CD24 − surface marker phenotype are enriched in tumor-initiating cells 31 . In the parental CN34 and MDA231 cell lines and in their lung metastatic derivatives, ~90% of the population is CD44 + CD24 − ( Supplementary Fig. 11 and ref. 32). TNC depletion did not change the CD44 + CD24 − population ratio in these cells (Supplementary Fig. 11) . Moreover, TNC depletion did not affect the expression of NANOG, OCT4 and SOX2 (Fig. 4c  and Supplementary Fig. 12 ). These genes encode transcription factors that are essential for the maintenance of pluripotency in stem cells 24, 27 . However, TNC depletion strongly suppressed the expression of LGR5 and MSI1 (Fig. 4c). LGR5 (ref. 29) and MSI1 (ref. 28) encode signal transduction components of the WNT and NOTCH pathways, respectively, which provide essential signals to stem and progenitor cells.
Knocking down MSI1 or LGR5 (Supplementary Fig. 13a,b) significantly reduced the lung metastatic efficiency of MDA231-LM2 and CN34-LM1 cells (Fig. 4d and Supplementary Fig. 13c) . Moreover, the combined knockdown of both genes led to even further reduction In contrast, the mammary differentiation marker GATA3 and the TNC-and metastasis-suppressor miRNA miR-335 were downregulated in oncospheres (e). n = 9-10 pleural fluid-derived cell samples. All P values were calculated by paired Wilcoxon signed rank test (two tailed). Whiskers represent minimum and maximum values. in lung colonization. However, depletion of LGR5 and MSI1 did not alter the CD44 + CD24 − profile of the cells (Supplementary Fig. 14) . Together, these results suggest that TNC is dispensable for the expression of pluripotency transcriptional enforcers in breast cancer cells but is required for expression of stem or progenitor cell signal transducers that support metastasis initiation by these cells.
TNC enhances WNT and NOTCH signaling in breast cancer cells TNC has a complex molecular architecture consisting of a radial hexamer in which each monomer comprises an N-terminal TNC assembly domain, followed by 14 epidermal growth factor (EGF)-like repeats, up to 17 alternatively spliced fibronectin-like repeats and a C-terminal fibrinogen-like domain. The TNC hexabrachion binds to extracellular matrix fibronectin and periostin 11 , and to integrins, EGF receptors, syndecan-4 and other membrane proteins 12 , many of which are expressed in the CN34 and MDA231 breast cancer cells (Supplementary Table 1 ). These interactions have the potential to affect key pathways in the cell. We analyzed LGR5 and MSI1 expression in response to WNT3A in oncospheres.
LGR5 is a key target of the WNT-T cell factor (TCF) pathway in adult stem cells 29 . Whereas addition of WNT3A did not alter the expression of MSI1 (data not shown), it strongly increased the expression of LGR5 and two other typical WNT target genes, those encoding lymphoid enhancer-binding factor 1 (LEF1) and axis inhibition protein 2 (AXIN2), which encode feedback regulators of WNT signaling (Fig. 5a) . This effect was blocked by the WNT inhibitor dickkopf homolog 1 (DKK1) recombinant protein (Supplementary Fig. 15) . Notably, the knockdown of TNC markedly reduced the response of LGR5 to WNT3A but had little or no effect on the response of LEF1 and AXIN2 (Fig. 5a) . These results suggest that TNC specifically modulates a component of the LGR5 response to WNT.
MSI1 is an RNA-binding protein that inhibits translation of the NOTCH pathway inhibitor NUMB 33 . NOTCH signaling is implicated in the expansion of the luminal progenitor compartment of the mammary epithelium 34 , which is the presumptive origin of basal breast carcinomas 35, 36 . In contrast to the role of NOTCH, activation of Janus kinase 2 (JAK2) and STAT5 by prolactin leads to alveolar differentiation and β-casein production 37 . Notably, TNC inhibits β-casein production in mammary epithelial cells 38 . On the basis of these clues, we tested the hypothesis that TNC may counteract JAK2-STAT5-dependent inhibition of NOTCH signaling. Treatment with the JAK2 inhibitor AG490 (ref. 39) or the STAT5 inhibitor nicotinoyl hydrazone 40 led to upregulation of MSI1 in the oncospheres (Fig. 5b,c) . This effect was particularly prominent in TNC knockdown cells in which the proportional increase was significantly higher than in controls. The expression of the NOTCH target genes HEY2, encoding a basic-helix-loop-helix protein that functions as downstream effector of NOTCH signaling and DTX1, encoding an E3-ubiquitin ligase that regulates NOTCH activity (also known as deltex1) in oncospheres (Supplementary Fig. 16 ) was decreased by TNC depletion (Fig. 5d and Supplementary Fig. 17) , and rescued by MSI1 overexpression in TNC-knockdown cells (Fig. 5e and  Supplementary Fig. 18 ). Furthermore, MSI1 expression partially rescued the lung colonization capacity (Fig. 5f,g ) and survival (Fig. 5h,i) of TNC-depleted breast cancer cells in the lungs. Thus, TNC suppressed JAK2-STAT5 signaling in breast cancer cells to enhance the expression of the NOTCH pathway component MSI1 and the prometastatic function of this pathway.
Association of TNC with MSI1 in clinical metastasis
To seek clinical evidence for the links among TNC, STAT5 and MSI1 uncovered in our experimental system, we applied a bioinformatics classifier based on a set of genes whose expression denotes cell stimulation by TNC 41 . When applied to gene expression data from a large cohort of primary breast tumors, this TNC gene signature (TNCS) classifier separated breast tumors into two groups (Supplementary Fig. 19 ). When applied to metastatic tissue samples, a majority (>80%) of metastatic samples from lung, bone and other sites scored positive for TNCS, whereas 48% of the primary tumors and only 16% of the brain metastases did (Fig. 6a) . This further strengthens the association of TNC with lung metastatic progression in patients, and suggested a role of TNC in metastasis to other sites. Intrigued by these results, we knocked down TNC in bone metastatic (MDA231-BoM1-1833, ref. Figs. 20a and 21a ) and determined their metastatic efficiency. TNC depletion significantly inhibited bone metastasis but not brain metastasis ( Fig. 6b and Supplementary Figs. 20b,c and 21b,c) .
We applied the TNC signature and compared the level of MSI1 expression in TNCS − versus TNCS + metastatic samples. MSI1 expression was significantly higher in TNCS + metastatic samples than in TNCS − metastases (Fig. 6c) . We also analyzed the correlation of the TNCS and a STAT5-dependent gene expression signature 44 ( Supplementary  Tables 2-4) . Unsupervised clustering of human metastasis samples showed that expression of this STAT5 signature was negatively correlated with expression of the TNCS (Supplementary Fig. 22 ). This negative correlation was even more apparent when gene set enrichment analysis (GSEA) 45 was applied to determine the representation of STAT5 signature genes within the TNCS + samples. Genes upregulated in the STAT5 signature were significantly (P = 0.006) underrepresented in the TNCS signature, and those downregulated in the signature significantly enriched (P = 0.027) (Fig. 6d) . Moreover, MSI1 expression was significantly lower in STAT5 signature-positive human metastases (Fig. 6e) . These results are in line with the functional evidence that TNC supports MSI1 expression in breast cancer cells by counteracting STAT5.
DISCUSSION
Our results place TNC on a metastasis-sustaining axis that engages the NOTCH and WNT pathways to support the fitness of initiating breast cancer cells during the establishment of lung metastases (Fig. 6f) . Cancer cell-derived TNC provides a head start for the viability of breast cancer cells in this setting, and remains critical until TNC from infiltrating myofibroblasts or other stromal sources accumulates in the expanding nodules. Circulating cancer cells that extravasate into the lungs may thus be selected for expression of TNC as an advantage trait. Cancer cell-derived TNC was not essential for the bulk growth of cells implanted as mammary tumors in our model systems. However, the presence of TNC at the invasive front 46 raises the possibility that TNC also supports breast cancer cells that locally migrate away from the bulk tumor mass as it supports cancer cells that reach the lung parenchyma or the bone marrow.
Our evidence suggests that TNC promotes the fitness of metastasisinitiating breast cancer cells by enhancing the expression of LGR5 and MSI1. Through these effects, TNC improves the performance of the NOTCH pathway and selectively enhances the LGR5 response to WNT in cancer cells. However, TNC seems dispensable for the expression of NANOG, OCT4 and SOX2, three transcription factors that are master enforcers of pluripotency and self-renewal in embryonic stem cells [24] [25] [26] [27] . TNC depletion also had no effect on the CD44 + CD24 − antigen profile, which is characteristic of breast cancer-initiating cells 31 . Thus, our evidence suggests that TNC specifically supports NOTCH and WNT signaling functions that are essential for the fitness of metastasis-initiating cells, but does not affect the expression of core transcriptional determinants of the stem cell phenotype. The differential effect of TNC on these two sets of molecular mediators not only sheds light on the contribution of an extracellular matrix component of the metastatic niche but also exemplifies how metastasis-initiating fitness and the metastasis-initiator phenotype are different, albeit interconnected, functions.
The complex molecular architecture of TNC and its ability to bind multiple types of cell adhesion receptors are thought to provide a coordinated set of environmental cues to cells in TNC-rich sites 12 . 
NOTCH WNT
HEY2, DTX1
LGR5 Enhanced metastatic fitness We show that the engagement of breast cancer cells by TNC protects NOTCH signaling from inhibition by JAK2-STAT5, and augments the ability of WNT to activate the expression of LGR5. The LGR5 effect may involve a TNC-dependent input on the unidentified factor that licenses stem cells to specifically activate this particular WNT target gene 47 . These links between TNC, NOTCH and WNT pathways are consistent with earlier reports observing a correlation of disease outcome with some of the components mechanistically brought together in our findings. Activity of the WNT pathway regulator β-catenin is associated with poor prognosis in breast cancer 48 .
The accumulation of NOTCH intracellular domain predicts early recurrence in ductal carcinoma in situ 49 . High expression of MSI1, NOTCH1 and the NOTCH ligand Jagged1 predicts poor overall survival 50, 51 . The NOTCH inhibitor NUMB is frequently underexpressed in breast cancer 52 . Furthermore, loss of STAT5 activity has been linked to poorly differentiated breast tumors 53 , and poor breast cancer survival 54 . These observations reinforce the pathway delineated in this study, in which TNC promotes metastasis by inhibiting JAK2-STAT5 signaling in breast cancer cells, relieving MSI1 from repression and thus enhancing NOTCH signaling activity. A possible explanation for the negative selection of TNCS and the lack of effect of TNC depletion on brain metastasis is that extracellular matrix molecules other than TNC 43 provide a metastasis niche in the unique microenvironment of the brain. By interfering with TNC production in our preclinical models, we suppressed the ability of micrometastatic colonies to survive and expand. Notably, TNC-deficient mice are viable and do not show severe developmental defects 55 . As an extracellular matrix component, TNC may be required for the viability of stem or progenitorlike cells mainly under stress conditions 56 . However, TNC may not be necessary for stem cell homeostasis otherwise. Considering that TNC is essential for the survival and outgrowth of disseminated cancer cells, but not essential in unstressed normal stem cell niches, therapeutically targeting TNC may provide a strategy for eliminating residual disease with minimal adverse effects and an approach for the combined inhibition of the NOTCH and WNT pathways in micrometastatic breast cancer.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. 43 ) and 293T cells in DMEM supplemented with 10% vol/vol FBS, 2 mM l-Glutamine, 100 IU ml −1 penicillin, 100 µg ml −1 streptomycin and 1 µg ml −1 amphotericin B. We maintained CN34-LM1 cells 8 and all primary pleural effusion samples in M199 medium containing 2.5% vol/vol FBS, 10 µg ml −1 insulin, 0.5 µg ml −1 hydrocortisone, 20 ng ml −1 EGF, 100 ng ml −1 cholera toxin, 0.5 µg ml −1 amphotericin B, 2 mM l-Glutamine, 100 IU ml −1 penicillin and 100 µg ml −1 streptomycin.
Pleural effusion samples. All procedures with human pleural effusion samples were approved by MSKCC Institutional Review Board. Procedures were done as described 57 . Briefly, we centrifuged the cells from pleural fluid at 300g for 10 min and treated them with ACK lysis buffer (LONZA) according to the manufacturer's instructions. We washed samples in PBS and plated cells.
Oncosphere formation. Oncospheres were grown by cultivating cancer cells derived from pleural effusions on ultralow-adhesive plates (Costar). We plated cells at 25,000 cells ml −1 in HuMEC medium (Invitrogen), supplemented with 5 µg ml −1 insulin, 20 ng ml −1 EGF, 10 ng ml −1 basic fibroblast growth factor and 2% vol/vol B27 (Invitrogen). Oncospheres were cultivated for 2 weeks.
Generation of various knockdown cells and MSI1 rescue cells.
We knocked down TNC, MSI1 and LGR5 with Mission TRC lentiviral vectors expressing shRNA against these gene products (Sigma-Aldrich). To generate MSI1 rescue cells, we amplified MSI1 by PCR from a cDNA clone (clone ID 100014977, Open Biosystems) and subcloned it into pBabe-hygromycin retroviral vector via BamH1 and Sal1 restriction sites. Production of retroviral particles is described in Supplementary Methods. mRNA and miRNA expression analysis. We isolated whole RNA from cancer cells using PrepEase RNA spin kit (USB). RNA (400 ng) was used to generate cDNA with High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Gene expression was analyzed using Taqman gene expression assays (Applied Biosystems). For miRNA analysis, we isolated RNA enriched for small RNA molecules using the mirVana miRNA Isolation Kit (Ambion). We used Taqman MicroRNA Reverse Transcription Kit (Applied Biosystems) to generate cDNA specific for miR-335 and RNU6B snRNA control from 10 ng of RNA. We carried out a quantitative PCR reaction on ABI 7900HT Fast RealTime PCR System and used the software SDS2.2.2 (Applied Biosystems) for analysis. Statistical analysis was done using Graphpad Prism 5 software.
Immunostaining. We stained frozen, paraformaldehyde-fixed tissue sections with antibodies to human tenascin (clone BC-24, Sigma-Aldrich), mouse tenascin (clone MTn-12, Sigma-Aldrich), α-smooth muscle actin (clone 1A4, Dako) and CD68 (clone FA-11, AbD Serotec). Paraffin-embedded, paraformaldehyde-fixed tissue sections were stained with antibodies to human tenascin (clone BC-24, Sigma-Adrich) and fascin-1 (Chemicon). Cleaved caspase 3 and phosphohistone H3 stainings were carried out by the MSKCC Molecular Cytology Core Facility. We used antibodies to cleaved caspase 3 (Cell Signaling) and phosphohistone H3 (Upstate).
